Our lead product candidate, PLN-74809, is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).


While expressed at very low levels in normal tissues, αvβ6 and αvβ1 integrins are upregulated in the pulmonary tissues of IPF patients, and in the liver tissues of PSC patients. Both of these integrins serve as activators of TGF-ß, leading to increased collagen production and, ultimately, fibrosis in these tissues. By blocking the activation of TGF-ß by both αvβ6 and αvβ1, we believe PLN-74809 may slow and potentially halt the progression of fibrosis in these patient populations.

View Graph

Program Highlights

  • PLN-74809 has shown favorable tolerability and pharmacokinetic profile in Phase 1 trials
  • Good oral bioavailability and long half-life are promising for potential once-daily dosing
  • Human biological proof-of-concept shown in a Phase 1b trial in healthy volunteers
  • Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients
  • Targeting of tissue-specific integrins is designed to maximize antifibrotic effect while avoiding systemic effects of TGF-β inhibition
  • There are currently only two existing FDA-approved therapies for IPF; while both have shown modest slowing of disease progression, medical need remains high
  • There are currently no FDA-approved therapies for PSC

Development Status

  • Global Phase 2a IPF and PSC trials enrolling
  • Granted Orphan Drug Designation for IPF and PSC
  • Preliminary data from Phase 2a IPF trial expected in mid 2022

Our Advanced Integrin Library

At Pliant, we have developed an industry-leading library of over 7,000 annotated integrin-binding molecules to probe the molecular drivers of fibrotic disease. With this library, we screen for activity against newly identified targets, to create a deep well of potential drug candidates.

Learn More